Diamicron Tablet (Gliclazide)
Gliclazide 80mg
Tablet · Prescription medication
SK Chemicals Co., Ltd.
MFDS item code 199701154 · Notified 1997.01.13
This product's status changed to Approval withdrawn on 2024.03.20. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of type 2 diabetes mellitus
This medication is used for patients with type 2 diabetes who have difficulty controlling blood sugar with diet and exercise alone. It helps effectively lower blood sugar and reduce the risk of complications. Regular use can improve blood sugar control and significantly aid in health management.
(Tablets)(Capsules) Adults: The initial dose of gliclazide is 40~80mg per day, administered orally in 1~2 divided doses. Thereafter, to achieve optimal control of the patient's blood glucose, the dose may be divided into 2 doses up to a maximum of 320mg per day, depending on the patient's condition. Do not exceed 160mg per dose. The dosage must be adjusted according to the patient's condition. Additional treatment may be required for obese patients or patients who do not respond adequately to this medication alone. (Modified-release tablets) Adults: Administer 30~120mg of gliclazide orally once daily in the morning, adjusting the dose according to blood glucose levels. If a dose is missed, do not increase the dose the following day. When taking this medication with other blood glucose-lowering agents, the dosage should be adjusted according to the individual patient's metabolic response (blood glucose, glycated hemoglobin). * Initial dose The recommended initial dose is 30mg per day. - If blood glucose control is satisfactory, maintain this dose as the maintenance dose. - If blood glucose control is unsatisfactory, the dose may be gradually increased to 60, 90, or 120mg per day at intervals of at least 1 month. If blood glucose has not decreased after 15 days of treatment, increase the dose from the end of the second week of treatment. Do not exceed 120mg per day. * When switching from gliclazide 80mg to gliclazide modified-release tablets 30mg, patients stabilized on gliclazide 80mg should be treated according to the principle that "gliclazide 80mg = gliclazide modified-release tablets 30mg." * When switching from another oral blood glucose-lowering agent to gliclazide modified-release tablets 30mg, consider the dose and half-life of the previous blood glucose-lowering agent. In general, switching can be done without any transitional washout period; therefore, start with 30mg of this medication per day and gradually increase the dose according to each patient's metabolic response, as described in the "Initial dose" section. For patients switching from a sulfonylurea blood glucose-lowering agent with a long half-life, a washout period of several days is necessary to prevent the risk of hypoglycemia due to additive effects of the two medications. * Concomitant use with other oral blood glucose-lowering agents This medication may be used in combination with biguanides, α-glucosidase inhibitors, or insulin. * Patients aged 65 years or older and patients with renal impairment This medication may be prescribed using the same administration method as for patients aged 65 years or younger with normal renal function. * Patients at risk of hypoglycemia - Undernourished or malnourished patients - Severe or moderate compensated endocrine disorders (anterior pituitary insufficiency, hypothyroidism, corticotropin insufficiency) - Discontinuation of long-term and/or high-dose corticosteroid therapy - Severe vascular disease (severe coronary heart disease, severe carotid artery disease, diffuse vascular disease) → It is recommended to initiate treatment at the minimum dose of 30mg per day.
This drug is a sulfonylurea and has the effect of lowering blood sugar, but there is a risk of hypoglycemia, so the dosage and administration must be strictly followed. Severe delayed hypoglycemia can occur, and in severe cases, hospitalization or glucose administration may be necessary. This drug should not be administered to patients with diabetic ketoacidosis, diabetic coma, type 1 diabetes, or those with severe hepatic or renal impairment. Additionally, it is advisable not to use this drug in patients with severe infections, severe trauma, pre- or post-surgery patients, or when food intake is decreased due to diarrhea or vomiting. Caution is required in women with allergic reactions to this drug or similar medications, pregnant or breastfeeding women, and patients taking certain medications. Elderly patients at high risk of hypoglycemia, patients with impaired renal or hepatic function, patients with endocrine diseases, irregular eaters, those who exercise excessively, and those who drink excessively should be administered this drug carefully. Symptoms of hypoglycemia may include weakness, tremors, headache, confusion, and visual disturbances, and immediate action should be taken if these symptoms occur. During the use of this drug, regular testing of blood sugar and urine sugar should be conducted to confirm the effectiveness of the medication and adjustments to dosing or treatment may be necessary. If hypoglycemia occurs, sugar should be ingested immediately, and in cases of severe hypoglycemia, rapid treatment at a hospital is required. This drug may interact with several other medications, so if other medications are being taken, consultation with a physician or pharmacist is essential. Pregnant or potentially pregnant women and breastfeeding mothers should not use this drug, and safety in children has not been established. Elderly patients should be monitored more carefully due to the increased risk of hypoglycemia caused by decreased physical function. In cases of overdose, hypoglycemic symptoms may occur; if symptoms are severe, immediate hospital treatment should be sought. During the use of this drug, caution should be exercised while driving or operating machinery due to the risk of hypoglycemia, especially in the early stages of treatment.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent air exposure, and it is recommended to store it at room temperature between 1 to 30 degrees Celsius. This way, the effectiveness of the medication can be maintained for a longer period.
White round tablet
100 tablets (20 tablets/PTPX5), 1000 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Gliclazide 80mg
Tablet · Prescription medication
SK Chemicals Co., Ltd.

Gliclazide 80mg
Tablet · Prescription medication
(Samchundang Pharmaceuticals Co., Ltd.)

Gliclazide 80mg
Tablet · Prescription medication
(Shinil Pharmaceutical Co., Ltd.)

Gliclazide 80mg
Tablet · Prescription medication
(Samnam Pharmaceutical Co., Ltd.)

Gliclazide 80mg
Tablet · Prescription medication
Teragen Itex Co., Ltd.

Gliclazide 30mg
Tablet · Prescription medication
Korea Servier Co., Ltd.

Gliclazide 60mg
Tablet · Prescription medication
Korea Servier Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.